NewGenIvf Group (NIVF) Fair Value & Analysis
Healthcare · US · Market cap $2.1M
NewGenIvf Group
NIVF · US
Fair value as of: Jul 17, 2026
From 8 valuation models · updated today
Fair value updated Jul 17, 2026, revised from $43.14 to $0.7005 (−98.4%) since Jun 24, 2026. Share price +91.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.4608 – $190.20 · fair‑value band $0.5255 – $0.8757 · the $1.34 price screens above the $0.7005 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
NewGenIvf Group (NIVF) currently trades at $1.34, while our model-based Fair Value estimate is $0.7005, implying the stock looks roughly 47.7% overvalued today. We read business quality at 28/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at $4.7M. Revenue grew 11.9% year over year. It earns a return on equity of 79.4%. Net debt stands at $4.1M. Fundamentals as of Jul 17, 2026
Our scenario range runs from $0.5255 (bear case) to $0.8757 (bull case); at $1.34, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at 28% fair-value upside, at -48%, NIVF screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing. It also offers IVF treatment; surrogacy and ancillary caring services, and value-added services comprising nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. The company provides its services through clinics. NewGenIvf Group Limited was founded in 2010 and is based in Bangkok, Thailand.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
NewGenIvf Group reported revenue of $4.7M in FY2025 versus $4.1M in FY2021, a compound +3.5%/yr. Reported net income was $9.9M in FY2025.
Is NIVF fairly valued? → Check now
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $209.68 | $255.97 | +22% |
| Tenet Healthcare Corporation THC | $164.77 | $280.85 | +70% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,305 | ₹2,546 | -69% |
| Fresenius Medical Care AG FME | €38.83 | €60.51 | +56% |
| Aier Eye Hospital Group 300015 | ¥8.49 | ¥10.83 | +28% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,010 | ₹283.61 | -72% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is NewGenIvf Group (NIVF) undervalued?
What is the fair value of NIVF?
What is the quality score of NIVF?
What is the revenue of NewGenIvf Group (NIVF)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full NewGenIvf Group analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.